Aluminum toxicity following IV use of oral methadone solution

Clinical Toxicology

Volumn 44, Issue 3, 2006, Pages 307-314

  Friesen, Marjorie S ^a,b,d   Purssell, Roy A ^b,c   Gair, Robert D ^a,b  

^a British Columbia Drug and Poison Information Centre   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d BC Drug and Poison Information Centre   (Canada)

Author keywords

Aluminum toxicity; Deferoxamine; Methadone; Utensil

Indexed keywords

ALUMINUM; DEFEROXAMINE; METHADONE; PHOSPHATE BINDING AGENT; CHELATING AGENT;

ADULT; ALUMINUM BLOOD LEVEL; ALUMINUM OVERLOAD; ARTICLE; ATAXIA; CASE REPORT; COGNITIVE DEFECT; COOKING; DIALYSATE; DYSARTHRIA; EXPOSURE; EYE TOXICITY; HEARING DISORDER; HEATING; HUMAN; INJECTION SITE REACTION; INTRAVENOUS DRUG ABUSE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LUNG TOXICITY; MALE; MUCORMYCOSIS; OPPORTUNISTIC INFECTION; OTOTOXICITY; SEIZURE; SYMPTOMATOLOGY; VISUAL DISORDER; YERSINIOSIS; BLOOD; INTRAVENOUS DRUG ADMINISTRATION; TOXICITY AND INTOXICATION; TREATMENT OUTCOME;

ATAXIA;

ADULT; ALUMINUM; CHELATING AGENTS; DEFEROXAMINE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHADONE; NEUROTOXICITY SYNDROMES; TREATMENT OUTCOME;

EID: 33745100820     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650600637077     Document Type: Article

References (104)

1. Alfrey AC, Mishell JM, Burks J, Contiguglia SR, Rudolph H, Lewin E, Holmes JH. Syndrome of dyspraxia and multifocal seizures associated with chronic hemodialysis. Trans Am Soc Artif Intern Organs 1972; 18:257-61, 266-267.
2. Mahurkar SD, Salta R, Smith EC, Dhar SK, Meyers L, Dunea G. Dialysis dementia. Lancet 1973; 1(7817):1412-1415.
3. Burks J, Huddlestone J, Lewin E, Alfrey A, Rudolph H. A progressive encephalopathy in chronic dialysis patients. Neurology 1974; 24:359.
4. Barratt LJ, Lawrence JR. Dialysis-associated dementia. Aust N Z J Med 1975; 5:62-65.
5. Platts MM, Hislop JS. Aluminium and dialysis encephalopathy. Lancet 1976; 2(7976):98.
6. Elliott HL, MacDougall AI, Fell GS. Aluminum toxicity syndrome. Lancet 1978; 1(8075):1203.
7. Ward MK, Feest TG, Ellis HA, Parkinson IS, Kerr DN. Osteomalacic dialysis osteodystrophy: evidence for a water-borne æteiological agent, probably aluminium. Lancet 1978; 1(8069):841-845.
8. Short AI, Winney RJ, Robson JS. Reversible microcytic hypochromic anaemia in dialysis patients due to aluminium intoxication. Proc Eur Dial Transplant Assoc 1980; 17:226-233.
9. Wing AJ, Brunner FP, Brynger H, Chantler C, Donckerwolcke RA, Gurland HJ, Jacobs C, Kramer P, Selwood NH. Dialysis dementia in Europe. Lancet 1980; 2(8187):190-192.
10. Arze RS, Parkinson IS, Cartlidge NE, Britton P, Ward MK. Reversal of aluminium dialysis encephalopathy after desferrioxamine treatment. Lancet 1981; 2(8255):1116.
11. Pogglitsch H, Petek W, Wawschinek O, Holzer W. Treatment of early stages of dialysis encephalopathy by aluminium depletion. Lancet 1981; 2(8259):1344-1345.
12. Nieboer E, Gibson BL, Oxman AD, Kramer JR. Health effects of aluminum: a critical review with emphasis on aluminum in drinking water. Environ Rev 1995; 3:29-81.
13. Winship KA. Toxicity of aluminium: a historical review, part 1. Adverse Drug React Toxicol Rev 1992; 11:123-141.
14. Yokel RA, McNamara PJ. Aluminum toxicokinetics: an updated minireview. Pharmacol Toxicol 2001; 88:159-167.
15. Pennington JA, Schoen SA. Estimates of dietary exposure to aluminium. Food Addit Contam 1995; 12:119-128.
16. Moore PB, Day JP, Taylor GA, Ferrier IN, Fifield LK, Edwardson JA. Absorption of aluminium-26 in Alzheimer's disease, measured using accelerator mass spectrometry. Dement Geriatr Cogn Disord 2000; 11:66-69.
17. Nolan CR, DeGoes JJ, Alfrey AC. Aluminum and lead absorption from dietary sources in women ingesting calcium citrate. South Med J 1994; 87:894-898.
18. Slanina P, Frech W, Ekström L-G, Lööf L, Slorach S, Cedergren A. Dietary citric acid enhances absorption of aluminum in antacids. Clin Chem 1986; 32:539-541.
19. Bakir AA, Hryhorczuk DO, Ahmed S, Hessl SM, Levy PS, Spengler R, Dunea G. Hyperaluminemia in renal failure: the influence of age and citrate intake. Clin Nephrol 1989; 31:40-44.
20. Van Landeghem GF, De Broe ME, D'Haese PC. Al and Si: their speciation, distribution, and toxicity. Clin Biochem 1998; 31:385-397.
21. Spence PS. Aluminum and its compounds. In: Spencer PS, Schaumberg HH, eds. Experimental and clinical neurotoxicology. 2nd ed; New York: Oxford University Press, 2000:142-151.
22. Yokel RA. Brain uptake, retention, and efflux of aluminum and manganese. Environ Health Perspect 2002; 110(Suppl 5):699-704.
23. Yokel RA. Aluminum chelation principles and recent advances. Coord Chem Rev 2002; 228:97-113.
24. Van Landeghem GF, D'Haese PC, Lamberts LV, Barata JD, De Broe ME. Aluminium speciation in cerebrospinal fluid of acutely aluminium intoxicated dialysis patients before and after desferrioxamine treatment; a step in the understanding of the element's neurotoxicity. Nephrol Dial Transplant 1997; 12:1692-1698.
25. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome, possible aluminum intoxication. New Engl J Med 1976; 294:184-188.
26. Berend K, van der Voet GB, de Wolff FA. Acute aluminum intoxication. Structure and Bonding 2002; 104:1-58.
27. Hémadi M, Miquel G, Kahn PH, Chahine J-M. Aluminum exchange between citrate and human serum transferrin and interaction with transferrin receptor 1. Biochemistry 2003; 42:3120-3130.
28. Greger JL, Sutherland JE. Aluminum exposure and metabolism. Crit Rev Clin Lab Sci 1997; 34:439-474.
29. Yokel RA, Wilson M, Harris WR, Halestrap AP. Aluminum citrate uptake by immortalized brain endothelial cells: implications for its blood-brain barrier transport. Brain Res 2002; 930:101-110.
30. Yokel RA, Allen DD, Ackley DC. The distribution of aluminum into and out of the brain. J Inorg Biochem 1999; 76:127-132.
31. Perl DP, Good PF. Uptake of aluminium into central nervous system along nasal-olfactory pathyways. Lancet 1987; 1(8540):1028.
32. Divine KK, Lewis JL, Grant PG, Bench G. Quantitative particle-induced X-ray emission imaging of rat olfactory epithelium applied to the permeability of rat epithelium to inhaled aluminum. Chem Res Toxicol 1999; 12:575-581.
33. Monteagudo FS, Cassidy MJ, Folb PI. Recent developments in aluminium toxicology. Med Toxicol 1989; 4:1-16.
34. Winship KA. Toxicity of aluminium: a historial review, part 2. Adverse Drug React Toxicol Rev 1993; 12:177-211.
35. Cannata-Andía JB, Fernádez-Martin JL. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant 2002; 17(Suppl 2):9-12.
36. Priest ND, Newton D, Day JP, Talbot RJ, Warner AJ. Human metabolism of aluminum-26 and gallium-67 injected as citrates. Hum Exp Toxicol 1995; 14:287-293.
37. Wilhelm M, Jäger DE, Ohnesorge FK. Aluminum toxicokinetics. Pharmacol Toxicol 1990; 66:4-9.
38. De Voto E, Yokel RA. The biological speciation and toxicokinetics of aluminum. Environ Health Perspect 1994; 102:940-951.
39. Cannata-Andía JB. Adynamic bone and chronic renal failure: an overview. Am J Med Sci 2000; 320:81-84.
40. rd ed; New York: Churchill Livingstone, 2000:2357-2373.
41. nd ed, Oxford, England: Oxford Medical Publications, 1998:1935-1954.
42. Smith EC, Mahurkar SD, Mamdani BH, Dunea G. Diagnosing dialysis dementia. Dial Transplant 1978; 7:1264, 1266, 1274.
43. Rosenbek JC, McNeil MR, Lemme ML, Prescott TE, Alfrey AC. Speech and language findings in a chronic hemodialysis patient: a case report. J Speech Hearing Dis 1975; 40:245-252.
44. th ed. Oxford, England: Oxford University Press, 2001:1-59.
45. Madison DP, Baehr ET, Bazell M, Hartman RW, Mahurkar SD, Dunea G. Communicative and cognitive deterioration in dialysis dementia: two case studies. J Speech Hear Disord 1977; 42:238-246.
46. Mahurkar SD, Meyers L, Cohen J, Kamath RV, Dunea G. Electroencephalographic and radionuclide studies in dialysis dementia. Kidney Int 1978; 13:306-315.
47. rd ed; Philadelphia: Lippincott Williams & Wilkins, 2004:381-392.
48. Jeffery EH, Abreo K, Burgess E, Cannata J, Greger JL. Systemic aluminum toxicity: effects on bone, hematopoietic tissue, and kidney. J Toxicol Environ Health 1996; 48:649-665.
49. Kanwar VS, Jenkins JJ, Mandrell BN, Furman WL. Aluminum toxicity following intravesical alum irrigation for hemorrhagic cystitis. Med Pediatr Oncol 1996; 27:64-67.
50. Phelps KR, Naylor K, Brien TP, Wilbur H, Haqqie SS. Encephalopathy after bladder irrigation with alum: case report and literature review. Am J Med Sci 1999:318:181-185.
51. Murphy CP, Cox RL, Harden EA, Stevens DA, Heye MM, Herzig RH. Encephalopathy and seizures induced by intravesical alum irrigations. Bone Marrow Transplant 1992; 10:383-385.
52. Nakamura H, Rose PG, Blumer JL, Reed MD. Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis. J Clin Pharmacol 2000; 40:296-300.
53. Hantson P, Mahieu P, Gersdorff M, Sindic CJ, Lauwerys R. Encephalopathy with seizures after use of aluminium-containing bone cement. Lancet 1994; 344(8937):1647.
54. Renard JL, Felten D, Béquet D. Post-otoneurosurgery aluminium encephalopathy. Lancet 1994; 344(8914):63-64.
55. Reusche E, Pilz P, Oberascher G, Lindner B, Egensperger R, Gloeckner K, Trinka E, Iglseder B. Subacute fatal aluminum encephalopathy after reconstructive otoneurosurgery: a case report. Hum Pathol 2001; 32:1136-1140.
56. Berend K, van der Voet G, Boer WH. Acute aluminum encephalopathy in a dialysis center caused by a cement mortar water distribution pipe. Kidney Int 2001; 59:746-753.
57. Kavoussi LR, Gelstein LD, Andriole GL. Encephalopathy and an elevated serum aluminum level in a patient receiving intravesical alum irrigation for severe urinary hemorrhage. J Urol 1986; 136:665-667.
58. Seear MD, Dimmick JE. Rogers PC. Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis. Urology 1990; 36:353-354.
59. Moreno A, Dominguez P, Dominquez C, Bullabriga A. High serum aluminium levels and acute reversible encephalopathy in a 4-year-old boy with acute renal failure. Eur J Pediatr 1991; 150:513-514.
60. Shoskes DA, Radzinski CA, Struthers NW, Honey RJ. Aluminum toxicity and death following intravesical alum irrigation in a patient with renal impairment. J Urol 1992; 147:697-699.
61. Sing K, Ahmed S, Moneer Y, Johnson B, Erickson T, Hryhorczuk D. Hyperaluminemia following bladder irrigation with alum: a case report. Vet Human Toxicol 1993; 35:340.
62. Perazella M, Brown E. Acute aluminum toxicity and alum bladder irrigation in patients with renal failure. Am J Kidney Dis 1993; 21:44-46.
63. Sedman AB, Miller NL, Warady BA, Lum GM, Alfrey AC. Aluminum loading in children with chronic renal failure. Kidney Int 1984; 26:201-204.
64. Zatta P, Zambenedetti P, Reusche E, Stellmacher F, Cester A, Albanese P, Meneghel G, Nordio M. A fatal case of aluminum encephalopathy in a patient with severe chronic renal failure not on dialysis. Nephrol Dial Transplant 2004; 19:2929-2931.
65. Bakir AA, Hryhorczuk DO, Berman E, Dunea G. Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. Trans Am Soc Artif Intern Organs 1986; 32:171-176.
66. Kirschbaum BB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum containing antacids. Am J Med Sci 1989; 297:9-11.
67. Campistol JM, Cases A, Botey A, Revert A. Acute encephalopathy in an uremic patient. Nephron 1989; 51:103-106.
68. Domingo JL. The use of chelating agents in the treatment of aluminum overload. Clin Toxicol 1989; 27:355-367.
69. Ackrill P, Ralston AJ, Day JP. Role of desferrioxamine in the treatment of dialysis encephalopathy. Kidney Int 1986; 29(Suppl 18):S104-S107.
70. De Broe ME, D'Haese PC, Couttenye MM, Van Landeghem GF, Lamberts LV. New insights and strategies in the diagnosis and treatment of aluminium overload in dialysis patients. Nephrol Dial Transplant 1993; 8(Suppl 1):47-50.
71. Ackrill P, Ralston AJ, Day JP, Hodge KC. Successful removal of aluminium from patient with dialysis encephalopathy. Lancet 1980; 2(8196):692-693.
72. Parajón JP, González EB, Cannata JB, Medel AS. A critical appraisal of the speciation of aluminum in serum by ultrafiltration. Trace Elem Med 1989; 6:41-46.
73. Canteros A, Diaz-Corte C, Fernandez-Martin JL, Gago E, Fernandez-Merayo C, Cannata J. Ultrafiltratable aluminium after very low doses of desferrioxamine. Nephrol Dial Transplant 1998; 13:1538-1542.
74. 26Al exposure. Toxicol Sci 2001; 64:77-82.
75. Verpooten GA, D'Haese PC, Boelaert JR, Becaus I, Lamberts LV, De Broe ME. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. Nephrol Dial Transplant 1992; 7:931-938.
76. De Broe ME, Drüeke TB, Ritz E. Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Nephrol Dial Transplant 1993; 8(Suppl 1):1-4.
77. Jorge C, Gil C, Possante M, Catarino MC, Cruz A, Andrade R, Teixeira R, Santos N, Ferreira A. Use of a desferrioxamine "microdose" to chelate aluminum in hemodialysis patients. Clin Nephrol 1999; 52:335-336.
78. Russo LS, Beale G, Sandroni S, Ballinger WE. Aluminium intoxication in undialysed adults with chronic renal failure. J Neurol Neurosurg Psychiatry 1992; 55:697-700.
79. McCauley J, Sorkin MI. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Nephrol Dial Transplant 1989; 4:110-114.
80. Sherrard DJ, Walker JV, Boykin JL. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. Am J Kidney Dis 1988; 12:126-130.
81. Lillevang ST, Pedersen FB. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Nephrol Dial Transplant 1989; 4:676.
82. Barata JD, D'Haese PC, Pires C, Lamberts LV, Simoes J, De Broe ME. Low-dose (5mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Nephrol Dial Transplant 1996; 11:125-132.
83. Porter JB. A risk-benefit assessment of iron-chelation therapy. Drug Safety 1997; 17:407-421.
84. Olivieri NF, Buncic R, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B, Taylor M, Freedman MH. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. New Engl J Med 1986; 314:869-873.
85. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989; 73:403-409.
86. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983; 2(8343):181-184.
87. Robins-Browne RM, Prpic JK. Desferrioxamine and systemic yersiniosis. Lancet 1983; 2(8363):1372.
88. Gallant T, Freedman MH, Vellend H, Francombe VH. Yersinia sepsis in patients with iron overload treated with deferoxamine. New Engl J Med 1986; 314:1643.
89. Boelaert JH, Vergauwe PL, Vandepitte JM. Mucormycosis infection in dialysis patients. Ann Intern Med 1987; 107:782-783.
90. Boelaert JH, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991; 18:660-667.
91. Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IY. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 1992; 339(8795):699-701.
92. Koren G, Bentu Y, Strong D, Harvey E, Klein J, Baumal R, Spielberg SP, Freedman MH. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1989; 143:1077-1080.
93. Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. Int J Hematol 1991; 54:371-375.
94. Veis JH, Contiguglia R, Klein M, Mishell J, Alfrey AC, Shapiro JI. Mucormycosis in deferoxamine-treated patients on dialysis. Ann Intern Med 1987; 107:258.
95. Goodill JJ, Abuelo JG. Mucormycosis - a new risk of deferoxamine therapy in dialysis patients with aluminum or iron overload? New Engl J Med 1987; 317:54.
96. Rubinstein M, Dupont P, Doppee JP, Dehon C, Ducobu J, Hainaut J. Ocular toxicity of desferrioxamine. Lancet 1985; 1(8432):817-818.
97. Cases A, Kelly J, Sabater J, Campistol JM, Torras A, Montoliu J, Lopez I, Revert L. Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine. Clin Nephrol 1988; 29:176-178.
98. Cannata JB, Serrano M, Fernandez Soto I, Fernandez Martin JL, Olaizola IR. Minimizing the risk of oral aluminium exposure in chronic renal failure. Contrib Nephrol 1989; 71:81-89.
99. Müller JP, Steinegger A, Schlatter C. Contribution of aluminium from packaging materials and cooking utensils to the daily aluminium intake. Z Lebensm Unters Forsch 1993; 197:332-341.
100. Liukkonen-Lilja H, Piepponen S. Leaching of aluminium from aluminium dishes and packages. Food Addit Contam 1992; 9:213-223.
101. Lin J-L, Yang Y-J, Yang S-S, Leu M-L. Aluminum utensils contribute to aluminum accumulation in patients with renal disease. Am J Kidney Dis 1997; 30:653-658.
102. Greger JL, Goetz W, Sullivan D. Aluminum levels in foods cooked and stored in aluminum pans, trays and foil. J Food Prot 1985; 48:772-777.
103. Humeniuk R, Ali R, McGregor C, Darke S. Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. Addiction 2003; 98:413-418.
104. Darke S, Ross J, Hall W. Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug Alcohol Depend 1996; 43:191-198.